Fulgent Genetics Reports Third Quarter 2017 Financial Results
Nov 06, 2017 21:05 pm UTC| Business
Revenue of $4.5 MillionGAAP Loss of $1.1 million, or $0.06 per ShareNon-GAAP loss of $442,000, or $0.02 per ShareAdjusted EBITDA loss of $458,000 TEMPLE CITY, Calif., Nov. 06, 2017 -- Fulgent Genetics (NASDAQ:FLGT)...
Presidio, Inc. Reports First Quarter Fiscal 2018 Results
Nov 06, 2017 21:05 pm UTC| Business
Delivers Strong Year-over-Year Earnings Growth Strong Growth in Security and Cloud Offerings NEW YORK, Nov. 06, 2017 -- Presidio, Inc. (NASDAQ:PSDO) ("Presidio"), a leading North American IT solutions provider...
Freshpet, Inc. Reports Third Quarter 2017 Financial Results
Nov 06, 2017 21:05 pm UTC| Business
SECAUCUS, N.J., Nov. 06, 2017 -- Freshpet, Inc. (“Freshpet” or the “Company”) (NASDAQ:FRPT) today reported financial results for its third quarter and nine months ended September 30, 2017. Third Quarter 2017...
Credit Acceptance Named to the Detroit Free Press 2017 Top Workplaces List
Nov 06, 2017 21:05 pm UTC| Business
Southfield, Michigan, Nov. 06, 2017 -- Credit Acceptance Corporation (NASDAQ: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) has been awarded a 2017 Top Workplaces honor by The Detroit...
Clarus Reports Third Quarter 2017 Results and Raises Full-Year Outlook
Nov 06, 2017 21:05 pm UTC| Business
SALT LAKE CITY, Nov. 06, 2017 -- Clarus Corporation (NASDAQ:CLAR) (“Clarus” and/or the “Company”), a diversified holding company which seeks opportunities to acquire and grow businesses that can generate attractive...
Gaia Reports Third Quarter 2017 Results
Nov 06, 2017 21:05 pm UTC| Business
BOULDER, Colo., Nov. 06, 2017 -- Gaia, Inc. (NASDAQ:GAIA), a conscious media company, reported financial results for the third quarter ended September 30, 2017. Third Quarter 2017 vs. Same Year-Ago Quarter 73%...
Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights
Nov 06, 2017 21:05 pm UTC| Business
ZilrettaTM (triamcinolone acetonide extended-release injectable suspension) received FDA approval for the management of osteoarthritis (OA) knee pain on October 6, 2017Product was made commercially available on October 23,...